Medicine and Health

Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/ human epidermal growth factor receptor 2-negative metastatic breast cancer

D. Shi, Y. Li, et al.

Discover the findings of this pivotal study evaluating the cost-effectiveness of sacituzumab govitecan versus chemotherapy for HR+/HER2- metastatic breast cancer. Despite increased life-years and QALYs, the study reveals significant cost challenges, presenting an ICER of $612,772/QALY. This research, conducted by Demin Shi, Yan Li, Xueyan Liang, and Lingyuan Chen, highlights the urgent need for price reductions to enhance SG's feasibility.

00:00

Playback language: English

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

J. Cortés, S. A. Hurvitz, et al.

$Efficacy of Olaparib in Treatment-Refractory, Metastatic Breast Cancer with Uncommon Somatic BRCA Mutations Detected in Circulating Tumor DNA$

Medicine and Health

Efficacy of Olaparib in Treatment-Refractory, Metastatic Breast Cancer with Uncommon Somatic BRCA Mutations Detected in Circulating Tumor DNA

J. Yoon, J. Ahn, et al.

Medicine and Health

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

K. Shitara, Y. Bang, et al.

Political Science

'Climate change concerns human survival...and justice in our international community': A corpus-based positive discourse analysis (PDA) of the largest developing nation's global involve/engagement discourses (re)told in interpreting

C. Gu

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny